Research output per year
Research output per year
Personal profile
Research interests
Dr. Weil’s professional interests include clinical parasitology, tropical medicine and global health. His laboratory conducts research on filarial nematode parasites that cause important tropical diseases such as elephantiasis and river blindness. This includes basic research on parasite biology and translational research to develop improved diagnostic tests and treatments. Weil serves as the Co-PI for the DOLF project (Funded by the Bill and Melinda Gates Foundation).
Clinical interests
Infectious diseases, tropical medicine
Mentoring
I am committed to increasing diversity in science.
Keywords
- COVID-19
Available to Mentor:
- PhD/MSTP Students
Fingerprint
Dive into the research topics where Gary Weil is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A novel antigen biomarker for detection of high-level of Loa loa microfilaremia
Greene, S. E., Huang, Y., Fischer, K., Rosa, B. A., Martin, J., Mitreva, M., Yates, D., Wanji, S., Kamgno, J., Budge, P. J., Weil, G. J. & Fischer, P. U., Sep 2024, In: PLoS neglected tropical diseases. 18, 9, e0012461.Research output: Contribution to journal › Article › peer-review
Open Access -
Implementation and Outcomes of a Pilot Collaborative Surgical Hydrocele Training in Côte d’Ivoire
Montes, K., Angoa, G., Bjerum, C. M., Guira, A., Kouadio, O. K., Ouattara, A. F., Weil, G. J., Fischer, P. U., Meite, A., Koudou, B. G. & Budge, P. J., 2024, In: American Journal of Tropical Medicine and Hygiene. 110, 1, p. 194-198 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
Opoku, N. O., Doe, F., Dubben, B., Fetcho, N., Fischer, K., Fischer, P. U., Gordor, S., Goss, C. W., Gyasi, M. E., Hoerauf, A., Hong, A., Kanza, E., King, C. L., Laryea, R., Lew, D., Seidu, M. A. & Weil, G. J., May 2023, In: PLoS neglected tropical diseases. 17, 5, e0011365.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
Greene, S. E., Huang, Y., Kim, W., Liebeskind, M. J., Chandrasekaran, V., Liu, Z., Deepak, P., Paley, M. A., Lew, D., Yang, M., Matloubian, M., Gensler, L. S., Nakamura, M. C., O'Hallaran, J. A., Presti, R. M., Whelan, S. P. J., Buchser, W. J., Kim, A. H. J. & Weil, G. J., Feb 2023, In: Journal of Clinical Virology Plus. 3, 1, 100135.Research output: Contribution to journal › Article › peer-review
Open Access -
Direct Proteomic Detection and Prioritization of 19 Onchocerciasis Biomarker Candidates in Humans
Rosa, B. A., Curtis, K., Gilmore, P. E., Martin, J., Zhang, Q., Sprung, R., Weil, G. J., Townsend, R. R., Fischer, P. U. & Mitreva, M., Jan 2023, In: Molecular and Cellular Proteomics. 22, 1, 100454.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations